2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 13, 2019

9:00AM-10:30AM: Abstract Number: 2869

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis

6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)

9:00AM-10:30AM: Abstract Number: 2871

Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study

6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: Abstract Number: 2885

An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases

6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

9:00AM-10:30AM: Abstract Number: 2873

Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland

6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: Abstract Number: 2865

Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States

6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)

9:00AM-10:30AM: Abstract Number: 2868

Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study

6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)

9:00AM-10:30AM: Abstract Number: 2887

Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus

6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

9:00AM-10:30AM: Abstract Number: 2859

Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA

6W012: RA – Etiology & Pathogenesis II (2858–2863)

9:00AM-10:30AM: Abstract Number: 2884

Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years

6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

9:00AM-10:30AM: Abstract Number: 2874

Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry

6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: Abstract Number: 2891

Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs

6W017: Health Services Research II: Health Economics (2888–2893)

9:00AM-10:30AM: Abstract Number: 2888

Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions

6W017: Health Services Research II: Health Economics (2888–2893)

9:00AM-10:30AM: Abstract Number: 2881

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)

9:00AM-10:30AM: Abstract Number: 2875

Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs

6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: Abstract Number: 2864

Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies

6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)

1
2
3
…
5
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].